Vanguard Portfolio Management
FBRX icon

Vanguard Portfolio Management’s Forte Biosciences FBRX Stock Holding History

Vanguard Portfolio Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.84M Buy
+133,771
New +$3.17M ﹤0.01% 2625

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Portfolio Management's FBRX Position: Q2 2026 in Review

Vanguard Portfolio Management opened a new position in Forte Biosciences (FBRX) in Q2 2026: 133,771 shares worth $2.84M. The stake represents ﹤0.01% of the portfolio and ranks #2625 among its holdings.

85 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • Vanguard Portfolio Management held 133,771 shares of Forte Biosciences worth $2.84M as of Q2 2026.
  • Forte Biosciences was a new Vanguard Portfolio Management position in Q2 2026.
  • Forte Biosciences made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2625 holding.
  • 85 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.